ArticleScientific reports2026
Combined minibeam and conventional radiotherapy reduces severe skin toxicity and improves tumor control.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Radiotherapy (RT) is an important tool for cancer treatment, enabling the delivery of curative doses to tumors while minimizing exposure to surrounding healthy tissue. Advances in beam delivery techniques and precise image-guidance systems have significantly reduced radiation exposure to normal tissues; however, treatment-related side effects remain a major limitation. To address these challenges, novel preclinical strategies are being explored. This study investigated minibeam radiotherapy (MBRT), which employs narrow (>100 microns) parallel beams of X-rays that produce a distinctive peak-and-valley dose distribution. We aimed to assess the efficacy and skin toxicity of MBRT compared to conventional radiotherapy (CONV), and to examine the role of macrophages in treatment response. We used a syngeneic glioblastoma mouse model, created by subcutaneously injecting [Formula: see text] GL261 cells into the flank, and applied single-fraction treatments of MBRT, CONV, or a combined minibeam-conventional regimen (MBRT-CONV). Irradiation was performed using a dedicated, image-guided small animal radiotherapy system, combined with a custom minibeam collimator. We evaluated tumor-specific survival and acute radiation-induced skin damage at macroscopic and microscopic levels through histopathological analysis to compare treatment outcomes. Our results showed that MBRT led to significantly reduced incidence and severity of skin ulceration compared to CONV at high single doses (25-30 Gy), although MBRT alone provided less effective tumor control. Additionally, we evaluated the effects of these treatments on healthy skin to assess the tissue-sparing potential of MBRT. Specifically, we investigated the impact of RT on macrophage recruitment in healthy skin. Based on the rapid inflammatory resolution observed in healthy skin, we implemented a delayed combined treatment strategy to enhance tumor suppression, by administering a CONV dose fraction seven days after the initial MBRT. Among the tested regimens, the 30 Gy MBRT + 5 Gy CONV combination achieved the most pronounced tumor growth delay and survival benefit, while maintaining a low incidence of toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.